博拓生物
(688767)
| 流通市值：60.21亿 | | | 总市值：60.21亿 |
| 流通股本：1.49亿 | | | 总股本：1.49亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 203,281,289.85 | 87,886,678.18 | 559,401,884.7 | 388,778,942.37 |
| 营业收入 | 203,281,289.85 | 87,886,678.18 | 559,401,884.7 | 388,778,942.37 |
| 二、营业总成本 | 196,373,351.51 | 81,933,026.26 | 361,376,540.17 | 287,401,539.14 |
| 营业成本 | 108,015,888.52 | 47,304,659.01 | 263,801,247.61 | 200,978,577.1 |
| 税金及附加 | 5,705,434.03 | 3,336,741.31 | 8,177,061.21 | 6,246,606.72 |
| 销售费用 | 20,141,584.55 | 9,127,384.34 | 30,872,292.78 | 18,163,369.19 |
| 管理费用 | 35,484,807.47 | 15,531,390.37 | 55,024,031.25 | 47,781,511.35 |
| 研发费用 | 39,993,735.67 | 15,119,864 | 63,574,584.74 | 43,944,660.52 |
| 财务费用 | -12,968,098.73 | -8,487,012.77 | -60,072,677.42 | -29,713,185.74 |
| 其中:利息费用 | - | - | 28,163.43 | 27,297.03 |
| 其中:利息收入 | 15,193,597.79 | - | 50,485,755.42 | 39,364,190.82 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -257,796.83 | 257,796.83 | - |
| 加:投资收益 | 3,124,451.6 | 1,940,651.9 | 6,789,817.56 | 4,967,633.59 |
| 资产处置收益 | 278,156.7 | -327,996.87 | -334,430.28 | -49,756.6 |
| 资产减值损失(新) | -900,521.34 | -64,258.26 | -22,794,092.71 | -9,368,841.1 |
| 信用减值损失(新) | 1,273,785.56 | 1,552,273.78 | -3,623,596.93 | -1,376,065.23 |
| 其他收益 | 1,870,571.8 | 421,618.24 | 15,084,941.4 | 3,821,710.24 |
| 四、营业利润 | 12,554,382.66 | 9,218,143.88 | 193,405,780.4 | 99,372,084.13 |
| 加:营业外收入 | 12,218.58 | 259,051.07 | 1,579,520.83 | 109,490.7 |
| 减:营业外支出 | 18,929.15 | 10,630.82 | 66,061.67 | 7,350.53 |
| 五、利润总额 | 12,547,672.09 | 9,466,564.13 | 194,919,239.56 | 99,474,224.3 |
| 减:所得税费用 | 1,806,609.4 | 1,814,655.95 | 28,143,838.01 | 12,835,035.44 |
| 六、净利润 | 10,741,062.69 | 7,651,908.18 | 166,775,401.55 | 86,639,188.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 10,741,062.69 | 7,651,908.18 | 166,775,401.55 | 86,639,188.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 12,402,352.13 | 8,732,428.9 | 169,515,470.99 | 89,211,721.37 |
| 少数股东损益 | -1,661,289.44 | -1,080,520.72 | -2,740,069.44 | -2,572,532.51 |
| 扣除非经常损益后的净利润 | 6,834,840.37 | 6,374,531.32 | 119,287,565.1 | 81,148,736.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.07 | 0.08 | 1.61 | 0.85 |
| (二)稀释每股收益 | 0.07 | 0.08 | 1.61 | 0.85 |
| 八、其他综合收益 | -411,378.99 | 84,292.17 | 1,399,752.91 | -1,791,331.89 |
| 归属于母公司股东的其他综合收益 | -413,982.97 | 83,280.99 | 1,295,506.85 | -1,845,569.84 |
| 九、综合收益总额 | 10,329,683.7 | 7,736,200.35 | 168,175,154.46 | 84,847,856.97 |
| 归属于母公司股东的综合收益总额 | 11,988,369.16 | 8,815,709.89 | 170,810,977.84 | 87,366,151.53 |
| 归属于少数股东的综合收益总额 | -1,658,685.46 | -1,079,509.54 | -2,635,823.38 | -2,518,294.56 |
| 公告日期 | 2025-08-29 | 2025-04-26 | 2025-04-26 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |